Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms

Cheng Len Sy; Pao Yu Chen; Chun Wen Cheng; Ling Ju Huang; Ching Hsun Wang; Tu Hsuan Chang; Yi Chin Chang; Chia Jung Chang; Ing Moi Hii; Yu Lung Hsu; Ya Li Hu; Pi Lien Hung; Chen Yen Kuo; Pei Chin Lin; Po Yen Liu; Ching Lung Lo; Shih Hao Lo; Pei Ju Ting; Chien Fang Tseng; Hsiao Wei Wang; Ching Hsiang Yang; Susan Shin Jung Lee; Yao Shen Chen; Yung Ching Liu; Fu Der Wang

doi:10.1016/j.jmii.2022.02.001

Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms

Cheng Len Sy, Pao Yu Chen, Chun Wen Cheng, Ling Ju Huang, Ching Hsun Wang, Tu Hsuan Chang, Yi Chin Chang, Chia Jung Chang, Ing Moi Hii, Yu Lung Hsu, Ya Li Hu, Pi Lien Hung, Chen Yen Kuo, Pei Chin Lin, Po Yen Liu, Ching Lung Lo, Shih Hao Lo, Pei Ju Ting, Chien Fang Tseng, Hsiao Wei WangChing Hsiang Yang, Susan Shin Jung Lee, Yao Shen Chen, Yung Ching Liu, Fu Der Wang

Taipei Medical University Shuang Ho Hospital

Research output: Contribution to journal › Review article › peer-review

38 Citations (Scopus)

Abstract

Antimicrobial drug resistance is one of the major threats to global health. It has made common infections increasingly difficult or impossible to treat, and leads to higher medical costs, prolonged hospital stays and increased mortality. Infection rates due to multidrug-resistant organisms (MDRO) are increasing globally. Active agents against MDRO are limited despite an increased in the availability of novel antibiotics in recent years. This guideline aims to assist clinicians in the management of infections due to MDRO. The 2019 Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group, comprising of infectious disease specialists from 14 medical centers in Taiwan, reviewed current evidences and drafted recommendations for the treatment of infections due to MDRO. A nationwide expert panel reviewed the recommendations during a consensus meeting in Aug 2020, and the guideline was endorsed by the Infectious Diseases Society of Taiwan (IDST). This guideline includes recommendations for selecting antimicrobial therapy for infections caused by carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales, and vancomycin-resistant Enterococcus. The guideline takes into consideration the local epidemiology, and includes antimicrobial agents that may not yet be available in Taiwan. It is intended to serve as a clinical guide and not to supersede the clinical judgment of physicians in the management of individual patients.

Original language	English
Pages (from-to)	359-386
Number of pages	28
Journal	Journal of Microbiology, Immunology and Infection
Volume	55
Issue number	3
DOIs	https://doi.org/10.1016/j.jmii.2022.02.001
Publication status	Published - Jun 2022

Keywords

CRAB
CRE
CRPA
Guideline
MDRO
VRE

ASJC Scopus subject areas

Immunology and Allergy
General Immunology and Microbiology
Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jmii.2022.02.001

Cite this

Sy, C. L., Chen, P. Y., Cheng, C. W., Huang, L. J., Wang, C. H., Chang, T. H., Chang, Y. C., Chang, C. J., Hii, I. M., Hsu, Y. L., Hu, Y. L., Hung, P. L., Kuo, C. Y., Lin, P. C., Liu, P. Y., Lo, C. L., Lo, S. H., Ting, P. J., Tseng, C. F., ... Wang, F. D. (2022). Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms. Journal of Microbiology, Immunology and Infection, 55(3), 359-386. https://doi.org/10.1016/j.jmii.2022.02.001

Sy, CL, Chen, PY, Cheng, CW, Huang, LJ, Wang, CH, Chang, TH, Chang, YC, Chang, CJ, Hii, IM, Hsu, YL, Hu, YL, Hung, PL, Kuo, CY, Lin, PC, Liu, PY, Lo, CL, Lo, SH, Ting, PJ, Tseng, CF, Wang, HW, Yang, CH, Lee, SSJ, Chen, YS, Liu, YC & Wang, FD 2022, 'Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms', Journal of Microbiology, Immunology and Infection, vol. 55, no. 3, pp. 359-386. https://doi.org/10.1016/j.jmii.2022.02.001

@article{e26146c3fbad47048ef11461c28248c8,

title = "Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms",

abstract = "Antimicrobial drug resistance is one of the major threats to global health. It has made common infections increasingly difficult or impossible to treat, and leads to higher medical costs, prolonged hospital stays and increased mortality. Infection rates due to multidrug-resistant organisms (MDRO) are increasing globally. Active agents against MDRO are limited despite an increased in the availability of novel antibiotics in recent years. This guideline aims to assist clinicians in the management of infections due to MDRO. The 2019 Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group, comprising of infectious disease specialists from 14 medical centers in Taiwan, reviewed current evidences and drafted recommendations for the treatment of infections due to MDRO. A nationwide expert panel reviewed the recommendations during a consensus meeting in Aug 2020, and the guideline was endorsed by the Infectious Diseases Society of Taiwan (IDST). This guideline includes recommendations for selecting antimicrobial therapy for infections caused by carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales, and vancomycin-resistant Enterococcus. The guideline takes into consideration the local epidemiology, and includes antimicrobial agents that may not yet be available in Taiwan. It is intended to serve as a clinical guide and not to supersede the clinical judgment of physicians in the management of individual patients.",

keywords = "CRAB, CRE, CRPA, Guideline, MDRO, VRE",

author = "Sy, {Cheng Len} and Chen, {Pao Yu} and Cheng, {Chun Wen} and Huang, {Ling Ju} and Wang, {Ching Hsun} and Chang, {Tu Hsuan} and Chang, {Yi Chin} and Chang, {Chia Jung} and Hii, {Ing Moi} and Hsu, {Yu Lung} and Hu, {Ya Li} and Hung, {Pi Lien} and Kuo, {Chen Yen} and Lin, {Pei Chin} and Liu, {Po Yen} and Lo, {Ching Lung} and Lo, {Shih Hao} and Ting, {Pei Ju} and Tseng, {Chien Fang} and Wang, {Hsiao Wei} and Yang, {Ching Hsiang} and Lee, {Susan Shin Jung} and Chen, {Yao Shen} and Liu, {Yung Ching} and Wang, {Fu Der}",

note = "Funding Information: This work funded by the Medical Foundation in Memory of Dr. Deh-Lin Cheng, Taiwan. We thank the members of the external expert review panel and expert consensus meeting for providing expert opinion and for the review of the guidelines. Members of the external expert panel (in alphabetical order): Feng-Yee Chang, Shan-Chwen Chang, Po-Yen Chen, Hsin Chi, Cheng-Hsun Chiu, Yin-Ching Chuang, Yu-Chung Chuang, Szu-Min Hsieh, Po-Ren Hsueh, Cheng-Hua Huang, Ching-Tai Huang, Li-Min Huang, Yhu-Chering Huang, Kao-Pin Hwang, Chen-Hsiang Lee, Ping-Ing Lee, Hsieh-Shong Leu, Jung-Chung Lin, Tzou-Yien Lin, Yi-Tsung Lin, Ching-Chuan Liu, Wang-Huei Sheng, Hung-Jen Tang, Ting-Shu Wu. Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = jun,

doi = "10.1016/j.jmii.2022.02.001",

language = "English",

volume = "55",

pages = "359--386",

journal = "Journal of Microbiology, Immunology and Infection",

issn = "1684-1182",

publisher = "Elsevier Taiwan LLC",

number = "3",

}

TY - JOUR

T1 - Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms

AU - Sy, Cheng Len

AU - Chen, Pao Yu

AU - Cheng, Chun Wen

AU - Huang, Ling Ju

AU - Wang, Ching Hsun

AU - Chang, Tu Hsuan

AU - Chang, Yi Chin

AU - Chang, Chia Jung

AU - Hii, Ing Moi

AU - Hsu, Yu Lung

AU - Hu, Ya Li

AU - Hung, Pi Lien

AU - Kuo, Chen Yen

AU - Lin, Pei Chin

AU - Liu, Po Yen

AU - Lo, Ching Lung

AU - Lo, Shih Hao

AU - Ting, Pei Ju

AU - Tseng, Chien Fang

AU - Wang, Hsiao Wei

AU - Yang, Ching Hsiang

AU - Lee, Susan Shin Jung

AU - Chen, Yao Shen

AU - Liu, Yung Ching

AU - Wang, Fu Der

N1 - Funding Information: This work funded by the Medical Foundation in Memory of Dr. Deh-Lin Cheng, Taiwan. We thank the members of the external expert review panel and expert consensus meeting for providing expert opinion and for the review of the guidelines. Members of the external expert panel (in alphabetical order): Feng-Yee Chang, Shan-Chwen Chang, Po-Yen Chen, Hsin Chi, Cheng-Hsun Chiu, Yin-Ching Chuang, Yu-Chung Chuang, Szu-Min Hsieh, Po-Ren Hsueh, Cheng-Hua Huang, Ching-Tai Huang, Li-Min Huang, Yhu-Chering Huang, Kao-Pin Hwang, Chen-Hsiang Lee, Ping-Ing Lee, Hsieh-Shong Leu, Jung-Chung Lin, Tzou-Yien Lin, Yi-Tsung Lin, Ching-Chuan Liu, Wang-Huei Sheng, Hung-Jen Tang, Ting-Shu Wu. Publisher Copyright: © 2022

PY - 2022/6

Y1 - 2022/6

N2 - Antimicrobial drug resistance is one of the major threats to global health. It has made common infections increasingly difficult or impossible to treat, and leads to higher medical costs, prolonged hospital stays and increased mortality. Infection rates due to multidrug-resistant organisms (MDRO) are increasing globally. Active agents against MDRO are limited despite an increased in the availability of novel antibiotics in recent years. This guideline aims to assist clinicians in the management of infections due to MDRO. The 2019 Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group, comprising of infectious disease specialists from 14 medical centers in Taiwan, reviewed current evidences and drafted recommendations for the treatment of infections due to MDRO. A nationwide expert panel reviewed the recommendations during a consensus meeting in Aug 2020, and the guideline was endorsed by the Infectious Diseases Society of Taiwan (IDST). This guideline includes recommendations for selecting antimicrobial therapy for infections caused by carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales, and vancomycin-resistant Enterococcus. The guideline takes into consideration the local epidemiology, and includes antimicrobial agents that may not yet be available in Taiwan. It is intended to serve as a clinical guide and not to supersede the clinical judgment of physicians in the management of individual patients.

AB - Antimicrobial drug resistance is one of the major threats to global health. It has made common infections increasingly difficult or impossible to treat, and leads to higher medical costs, prolonged hospital stays and increased mortality. Infection rates due to multidrug-resistant organisms (MDRO) are increasing globally. Active agents against MDRO are limited despite an increased in the availability of novel antibiotics in recent years. This guideline aims to assist clinicians in the management of infections due to MDRO. The 2019 Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group, comprising of infectious disease specialists from 14 medical centers in Taiwan, reviewed current evidences and drafted recommendations for the treatment of infections due to MDRO. A nationwide expert panel reviewed the recommendations during a consensus meeting in Aug 2020, and the guideline was endorsed by the Infectious Diseases Society of Taiwan (IDST). This guideline includes recommendations for selecting antimicrobial therapy for infections caused by carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales, and vancomycin-resistant Enterococcus. The guideline takes into consideration the local epidemiology, and includes antimicrobial agents that may not yet be available in Taiwan. It is intended to serve as a clinical guide and not to supersede the clinical judgment of physicians in the management of individual patients.

KW - CRAB

KW - CRE

KW - CRPA

KW - Guideline

KW - MDRO

KW - VRE

UR - http://www.scopus.com/inward/record.url?scp=85127851241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127851241&partnerID=8YFLogxK

U2 - 10.1016/j.jmii.2022.02.001

DO - 10.1016/j.jmii.2022.02.001

M3 - Review article

C2 - 35370082

AN - SCOPUS:85127851241

SN - 1684-1182

VL - 55

SP - 359

EP - 386

JO - Journal of Microbiology, Immunology and Infection

JF - Journal of Microbiology, Immunology and Infection

IS - 3

ER -

Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this